Applied DNA Sciences Inc. Restructures to Focus on Synthetic DNA Manufacturing, Implements Workforce Reduction
Reuters
Jun 30, 2025
<a href="https://laohu8.com/S/APDN">Applied DNA Sciences Inc</a>. Restructures to Focus on Synthetic DNA Manufacturing, Implements Workforce Reduction
Applied DNA Sciences Inc. has announced a strategic reorganization to focus on its synthetic DNA manufacturing business, LineaRx. As part of this realignment, the company has reduced its workforce by approximately 27% and ceased operations at its Applied DNA Clinical Labs, effective June 27, 2025. This reorganization is part of a broader effort to concentrate resources on LineaRx's growth, enhance its LineaDNA and LineaIVT platforms, and expand service offerings for biotherapeutic applications. The company anticipates a 23% reduction in annual payroll costs, partially offset by a $300,000 one-time charge for separation benefits. This move is expected to streamline operations and improve efficiency, positioning LineaRx as a key player in the synthetic DNA industry.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied DNA Sciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1044173) on June 30, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.